Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(6/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(6/week)
News
United States
(507/week)
Manufacturing
(335/week)
Energy
(278/week)
Technology
(347/week)
Other Manufacturing
(263/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Biohaven Pharmaceutical Holding Company Ltd.
Jan 29, 2020
Biohaven Announces Pricing Of $250 Million Public Offering Of Common Shares
Jan 28, 2020
Biohaven Announces Proposed Public Offering Of Common Shares
Jan 22, 2020
Biohaven's Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General
Dec 17, 2019
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
Dec 06, 2019
Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study
Dec 05, 2019
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office
Nov 04, 2019
Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
Nov 01, 2019
Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments
Oct 28, 2019
Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
Sep 18, 2019
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
Sep 10, 2019
Biohaven Advances NOJECTION(TM) Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
Sep 09, 2019
Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session
Aug 08, 2019
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
Aug 07, 2019
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
Jul 31, 2019
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
Jul 22, 2019
Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
Jul 19, 2019
Biohaven's Nurtec (riluzole) 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study
Jul 15, 2019
Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet
Jul 11, 2019
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Jul 11, 2019
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
‹‹
Page 3
››
Latest News
Apr 20, 2024
H2 Green Mining and Ohmium Sign Agreement to Boost Green Hydrogen in Chile
Apr 19, 2024
Churchill Serves as Sole Lead Arranger for a First Lien Credit Facility to Support Wynnchurch Capital’s...
Apr 19, 2024
Global Small Modular Reactor Market for Data Centers Industry Report 2024-2033: Hyperscale Data Centers to...
Apr 19, 2024
BWXT Announces Expansion of Cambridge Manufacturing Plant to Support Global Nuclear Power Market
Apr 19, 2024
Chemtrade Logistics Income Fund Declares April 2024 Distribution
Apr 19, 2024
MCR and BLT Complete $632 Million Refinancing of 53-Hotel Portfolio
Apr 19, 2024
Avangrid Thanks Southern Connecticut Gas Employee for 51 Years of Service
Apr 19, 2024
Construction Equipment Global Strategic Business Report 2024: Market to Reach $248.5 Billion by 2030 - Focus...
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events